Author Correction: High-dose nusinersen for spinal muscular atrophy: a phase 3 randomized trial

In the version of the article initially published, there were errors in the NfL data in Fig. 2, Table 2 and Extended Data Fig. 4. The original figures and table are available for comparison in the Supplementary information accompanying this amendment.In the Results, in the "Part B cohort with infantile-onset SMA: neurodegeneration" section, the text "compared with the ENDEAR matched sham group (30% reduction)" has been corrected to "compared with the ENDEAR matched sham group (32% reduction)", and "nominally significant P = 0.0050" has been corrected to "nominally significant P = 0.0075".In the "Part B cohort with later-onset SMA: neurodegeneration" section, the text "nominally significant P = 0.0495" has been corrected to "nominally significant P = 0.0047".